ÄÁÅÙÃ÷»ó¼¼º¸±â

COVID-19 Äڷγª¹ÙÀÌ·¯½º :  ´ç´Ü¹éÁúÀÇ ±Û¸®Ä­ ½Çµå¿Í ±¸Á¶ ¿¹Ãø ¹× Àΰ£ CD26°úÀÇ »óÈ£ÀÛ¿ë
COVID-19 Äڷγª¹ÙÀÌ·¯½º : ´ç´Ü¹éÁúÀÇ ±Û¸®Ä­ ½Çµå¿Í ±¸Á¶ ¿¹Ãø ¹× Àΰ£ CD26°úÀÇ »óÈ£ÀÛ¿ë
  • ÀúÀÚNaveen Vankadari , Jacqueline A. Wilce Àú
  • ÃâÆÇ»ç¾ÆÁø
  • ÃâÆÇÀÏ2020-07-12
  • µî·ÏÀÏ2020-12-21
º¸À¯ 1, ´ëÃâ 0, ¿¹¾à 0, ´©Àû´ëÃâ 9, ´©Àû¿¹¾à 0

Ã¥¼Ò°³

The recent outbreak of pneumonia-causing COVID-19 in China is an urgent global
public health issue with an increase in mortality and morbidity. Here we report
our modelled homo-trimer structure of COVID-19 spike glycoprotein in both closed
(ligand-free) and open (ligand-bound) conformation, which is involved in host cell
adhesion. We also predict the unique N- and O-linked glycosylation sites of spike
glycoprotein that distinguish it from the SARS and underlines shielding and
camouflage of COVID-19 from the host the defence system. Furthermore, our
study also highlights the key finding that the S1 domain of COVID-19 spike
glycoprotein potentially interacts with the human CD26, a key immunoregulatory
factor for hijacking and virulence. These findings accentuate the unique features of
COVID-19 and assist in the development of new therapeutics.
µî·Ï»óÇ¥
Emerging Microbes

¸ñÂ÷

Á¦ 1Æí Äڷγª¹ÙÀÌ·¯½º Á¤ÀÇ
1. Äڷγª¹ÙÀÌ·¯½º°¨¿°Áõ-19(Covid-19) Á¤º¸ 7
2. Äڷγª¹ÙÀÌ·¯½º ºÐ·ù ¹× Æ¯¼º 9
3. Äڷγª¹ÙÀÌ·¯½º ÀüÀÚÇö¹Ì°æ ÇüÅ 11
4. Äڷγª¹ÙÀÌ·¯½º ±¸Á¶ (Covid-19 Organization) 13
5. Äڷγª19: È¯°æ¿¡ Áö¼ÓÀûÀΠ¿µÇâÀ» ¹ÌÄ¥±î? 19
6. Ä¡·á¹ý(Therapeutical Method) 22

Á¦ 2Æí ¿¬±¸³í¹®
Emerging WuHan (COVID-19) coronavirus: glycan shield and structure
prediction of spike glycoprotein and its interaction with human CD26

1. Abstract 23
2. Introduction 23
3. Acknowledgements 26
4. Disclosure statement 26
5. References 26

ÇÑÁÙ ¼­Æò